Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancerGuoshun Luo, Hua Xiang, Shengnan Ren et al.|European Journal of Medicinal Chemistry|2021Cited by 20
The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expressionShengnan Ren, Zhao-xia Wang|Acta Biochimica et Biophysica Sinica|2022Cited by 10